Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · enVVeno Medical Corp (NVNO)

enVVeno Medical receives FDA IDE approval for pivotal study of non-surgical venous valve

Positive Impact 3 of 5 other Written later

enVVeno Medical said the FDA approved its Investigational Device Exemption application, allowing a pivotal U.S. study of its enVVe non-surgical replacement venous valve for severe deep Chronic Venous Insufficiency. The company said it had approximately $25 million in cash and investments as of March 31, 2026, expected to fund operations into the third quarter of 2027.

Key points

  • FDA approved the IDE application for the TAVVE pivotal study, announced April 29, 2026.
  • First stage will enroll 10 patients, with 30-day safety results submitted to the FDA; second stage will enroll 220 patients (165 receiving the enVVe valve, 55 in a control arm).
  • Study will enroll at up to 40 U.S. clinical sites; first stage is expected to commence later this year.
  • Cash and investments were approximately $25 million as of March 31, 2026, expected to fund operations into Q3 2027.

The filing

CompanyenVVeno Medical Corp (NVNO)
Form8-K, current report
Filed with the SECApr 29, 2026, 8:25 AM ET
Accession number0001493152-26-019485

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.